Latest Laquinimod Stories
MarketReportsOnline.com offers “Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)” research that analyzes the global market sizing and growth of multiple sclerosis in
Transparency Market Research add new "Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018" market research report to its
Save the neurons! A new study suggests laquinimod triggers immune cells within the central nervous system produce and release brain-derived neurotrophic factor, BDNF, contributing to the repair or survival of neurons; therefore limiting brain damage.
Laquinimod is an orally available synthetic compound that has been successfully evaluated in phase II/III clinical studies for the treatment of relapsing-remitting multiple sclerosis (RRMS).
This report provides perspective on the MS landscape in light of Merck Seronoâ€™s decision to discontinue development and marketing of cladribine for MS. Scottsdale, AZ (PRWEB) June 27, 2011 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled â€œThought Leader Insight & Analysis: Multiple Sclerosis,â€ designed to provide critical strategic insight for pharma and biotech companies...
The drug laquinimod reduced the number of instances in relapses for individuals with multiple sclerosis (MS) in a long-term, phase III clinical study involving 1,106 participants with relapsing-remitting MS in 24 countries.
Lund, Sweden, November 6, 2008 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11 at the New York Palace Hotel in New York City, US.
Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the field of rheumatology, held in San Francisco October 24-29*.
Lund, Sweden, October 17, 2008 - Active Biotech AB's (NASDAQ OMX Nordic: ACTI) collaboration partner MediGene AG (Frankfurt, Prime Standard: MDG) today announce information regarding the candidate drug RhuDex(R) for the treatment of rheumatoid arthritis.
Teva Pharmaceutical Industries has reported new data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis, which demonstrated a significant reduction in the mean number of gadolinium-enhancing lesions in both patients who switched from placebo to laquinimod and patients who continued with their initial laquinimod dose.